FAIR Act could boost U.S. rare‑disease trial access and restore biotech leadership

In a recent BioSpace podcast, host Jennifer C. Smith‑Parker talked with Max Bronstein of Aviva Strategies and Teresa Barnes of PF Warriors about a growing problem: U.S. patients are increasingly unable to enroll in rare‑disease clinical trials that are taking place overseas.

The guests argued that the proposed FAIR Act, which would create accelerated and harmonized regulatory reviews for such studies, could close the gap. By streamlining the approval process, the legislation aims to bring lifesaving trials to American patients more quickly and help the United States retain its biotech leadership.

While the discussion reflected optimism about the act’s potential impact, the participants noted that implementation will require coordination among regulators, sponsors, and advocacy groups. The podcast concluded that the FAIR Act could be a key policy tool for preserving U.S. competitiveness in rare‑disease research.